OBJECTIVE: To determine the prognostic value of pT3 bladder urothelial carcinoma substaging in patients without lymphatic involvement. PATIENTS AND METHODS: Pathologic and clinical data were reviewed on patients who underwent radical cystectomy for urothelial carcinoma between 1991 and 2010. Of the 460 reviewed patients, 74 patients were diagnosed with pathologic T3No urothelial carcinoma of the bladder. The impact of pathologic substaging (pT3a vs. pT3b) was examined to determine the effect on overall and disease-specific survival. RESULTS: Five years disease-specific and overall survival rates were 46.9 % and 39.6 % for patients with pT3aNo tumor, whereas these ratios were 34.4 and 30.3 %, respectively, for patients with pT3bNo tumor (p > 0.05). Mean disease-specific survival time was 43.94 ± 6.50 months for pT3aNo, while it was 39.01 ± 7.19 months for pT3bNo (p = 0.539). In multivariate cox regression analysis, age (p = 0.459), gender (p = 0.710), urinary diversion type (p = 0.088), and pT3 substaging (p = 0.554) were not noticed as an independent predictive factor for survival. CONCLUSION: Macroscopic extravesical extension (pT3b) is not associated with a worse outcome than pT3a disease in lymph node-negative cases of bladder urothelial carcinoma.
OBJECTIVE: To determine the prognostic value of pT3bladder urothelial carcinoma substaging in patients without lymphatic involvement. PATIENTS AND METHODS: Pathologic and clinical data were reviewed on patients who underwent radical cystectomy for urothelial carcinoma between 1991 and 2010. Of the 460 reviewed patients, 74 patients were diagnosed with pathologic T3No urothelial carcinoma of the bladder. The impact of pathologic substaging (pT3a vs. pT3b) was examined to determine the effect on overall and disease-specific survival. RESULTS: Five years disease-specific and overall survival rates were 46.9 % and 39.6 % for patients with pT3aNotumor, whereas these ratios were 34.4 and 30.3 %, respectively, for patients with pT3bNo tumor (p > 0.05). Mean disease-specific survival time was 43.94 ± 6.50 months for pT3aNo, while it was 39.01 ± 7.19 months for pT3bNo (p = 0.539). In multivariate cox regression analysis, age (p = 0.459), gender (p = 0.710), urinary diversion type (p = 0.088), and pT3 substaging (p = 0.554) were not noticed as an independent predictive factor for survival. CONCLUSION: Macroscopic extravesical extension (pT3b) is not associated with a worse outcome than pT3a disease in lymph node-negative cases of bladder urothelial carcinoma.
Authors: J P Stein; G Lieskovsky; R Cote; S Groshen; A C Feng; S Boyd; E Skinner; B Bochner; D Thangathurai; M Mikhail; D Raghavan; D G Skinner Journal: J Clin Oncol Date: 2001-02-01 Impact factor: 44.544
Authors: Derya Tilki; Robert S Svatek; Pierre I Karakiewicz; Giacomo Novara; Michael Seitz; Guru Sonpavde; Amit Gupta; Wassim Kassouf; Yves Fradet; Vincenzo Ficarra; Eila Skinner; Yair Lotan; Arthur I Sagalowsky; Christian G Stief; Oliver Reich; Shahrokh F Shariat Journal: J Urol Date: 2010-06-17 Impact factor: 7.450
Authors: Patrick J Bastian; Georg C Hutterer; Shahrokh F Shariat; Craig G Rogers; Ganesh S Palapattu; Yair Lotan; Amnon Vazina; Gilad E Amiel; Amit Gupta; Arthur I Sagalowsky; Seth P Lerner; Mark P Schoenberg; Pierre I Karakiewicz Journal: BJU Int Date: 2007-09-10 Impact factor: 5.588
Authors: Marcus L Quek; John P Stein; Peter E Clark; Siamak Daneshmand; Gus Miranda; Jie Cai; Susan Groshen; Richard J Cote; Gary Lieskovsky; David I Quinn; Donald G Skinner Journal: J Urol Date: 2004-02 Impact factor: 7.450
Authors: Kelly J Boudreaux; Sam S Chang; William T Lowrance; Jon A Rumohr; Daniel A Barocas; Michael S Cookson; Joseph A Smith; Peter E Clark Journal: Cancer Date: 2009-02-15 Impact factor: 6.860